RxDoctor Payments Data

David Flores, MD

Pulmonary Disease · Jersey City, NJNPI 1710943154

Payments from drug & device makers

$11,060in general payments, 2019–2025

Across 280 payments — averaging $39.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Intuitive Surgical$1K
  • AstraZeneca$1K
  • Gilead$732
  • Olympus Corporation Of The Americas$465
  • Pulmonx Corporation$444
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$1,45413%
  • Food & beverage$9,60687%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,060 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$92,537
Medicare patients
227
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate20$259,577
AdempasRiociguat13$114,411
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$113,763
Incruse ElliptaUmeclidinium Bromide92$31,955
Breo ElliptaFluticasone/Vilanterol55$26,573
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$25,625
Fluticasone-SalmeterolFluticasone Propion/Salmeterol158$22,691
Combivent RespimatIpratropium/Albuterol Sulfate23$13,896
SymbicortBudesonide/Formoterol Fumarate58$13,353
Spiriva HandihalerTiotropium Bromide16$11,108
Spiriva RespimatTiotropium Bromide19$9,868
Albuterol Sulfate HfaAlbuterol Sulfate369$8,957
Arnuity ElliptaFluticasone Furoate24$5,426
Ventolin HfaAlbuterol Sulfate77$5,172
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat$135$283,34262 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$2,717$182,554326 claims
BayerAdempas$27$114,41113 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,265$38,978100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →